Peptide candidates for the development of therapeutics and vaccines against β-coronavirus infection

References

• Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, people’s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358. DOI:10.1016/S0140-6736(03)14630-2.
   PubMed Web of Science ®Google Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. Accessed 2 November 2020. https://www.nejm.org/doi/full/10.1056/nejmoa2001017
   PubMed Web of Science ®Google Scholar
• Bui LM, Thi Thu Phung H, Ho Thi TT, et al. Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review. Bioengineered. 2021;12:8594–8613.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Coronavirus disease (COVID-19) situation reports. 2020 [cited 2020 Nov 2]; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• Liu YC, Kuo RL, Shih SR. COVID-19: the first documented coronavirus pandemic in history. Biomed J. 2020;43:328–333.
   PubMed Web of Science ®Google Scholar
• Chu D-T, Vu Ngoc S-M, Vu Thi H, et al. COVID-19 in Southeast Asia: current status and perspectives. Bioengineered. 2022;13:3797–3809.
   PubMed Web of Science ®Google Scholar
• Boni MF, Lemey P, Jiang X, et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat Microbiol. 2020;5:1408–1417.
   PubMed Web of Science ®Google Scholar
• Liu DX, Liang JQ, Fung TS. Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Encyclopedia of Virology 4 th edition . In Bamford DH, Zuckerman M, (Eds). Amsterdam, Netherlands: Elsevier. 2021;428–440 978-0-12-814516-6 . Accessed 07 April 2021. doi:10.1016/b978-0-12-809633-8.21501-x https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204879/
   Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. DOI:10.1016/S0140-6736(20)30251-8.
   PubMed Web of Science ®Google Scholar
• Kaddoura M, AlIbrahim M, Hijazi G, et al. COVID-19 therapeutic options under investigation. Front Pharmacol. 2020;11:1196.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Sengupta PS, Panda SK, et al. Designing abhiSCoVac - A single potential vaccine for all ‘corona culprits’: immunoinformatics and immune simulation approaches. J Mol Liq. 2022;351:118633.
   PubMed Web of Science ®Google Scholar
• Toyoshima Y, Nemoto K, Matsumoto S, et al. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020;65:1075–1082.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Das NC, Patra R, et al. In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans. J Med Virol. 2021;93:2476–2486.
   PubMed Web of Science ®Google Scholar
• Muralidar S, Ambi SV, Sekaran S, et al. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100.
   PubMed Web of Science ®Google Scholar
• Iwata-Yoshikawa N, Okamura T, Shimizu Y, et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol. 2019;93:1815–1833.
   PubMed Web of Science ®Google Scholar
• Padhi S, Massi M, Chourasia R, et al. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS -CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors. Eur J Pharmacol. 2020;890:173648.
   PubMed Web of Science ®Google Scholar
• Pandey A, Nikam AN, Shreya AB, et al. Potential therapeutic targets for combating SARS-CoV-2: drug repurposing, clinical trials and recent advancements. Life Sci. 2020;256:117883.
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20:122–128.
   PubMed Web of Science ®Google Scholar
• Goodwin D, Simerska P, Toth I. Peptides as therapeutics with enhanced bioactivity. Curr Med Chem. 2012;19:4451–4461.
   PubMed Web of Science ®Google Scholar
• Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect Public Health. 2020;13:1405–1414.
   PubMed Web of Science ®Google Scholar
• Yu Z, Kan R, Ji H, et al. Identification of tuna protein-derived peptides as potent SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation. Food Chem. 2020;342:128366.
   PubMed Web of Science ®Google Scholar
• Shartouny JR, Jacob J. Mining the tree of life: host defense peptides as antiviral therapeutics. Semin Cell Dev Biol. 2019;88:147–155.
   PubMed Web of Science ®Google Scholar
• Woon AP, Purcell AW. The use of proteomics to understand antiviral immunity. Semin Cell Dev Biol. 2018;84:22–29.
   PubMed Web of Science ®Google Scholar
• Sharma S, Singh A, Sharma S, et al. Functional foods as a formulation ingredients in beverages: technological advancements and constraints. Bioengineered. 2021;12:11055–11075.
   PubMed Web of Science ®Google Scholar
• Gmoser R, Fristedt R, Larsson K, et al. From stale bread and brewers spent grain to a new food source using edible filamentous fungi. Bioengineered. 2020;11:582–598.
   PubMed Web of Science ®Google Scholar
• Wikandari R, Manikharda BS, Ningrum A, et al. Application of cell culture technology and genetic engineering for production of future foods and crop improvement to strengthen food security. Bioengineered. 2021;12:11305–11330.
   PubMed Web of Science ®Google Scholar
• Souza PFN, Lopes FES, Amaral JL, et al. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. Int J Biol Macromol. 2020;164:66–76.
   PubMed Web of Science ®Google Scholar
• Lim HX, Lim J, Jazayeri SD, et al. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomed J. 2021;44(1):18–30.
   PubMed Web of Science ®Google Scholar
• Hemmati S, Behzadipour Y, Haddad M. Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors. Infect Genet Evol. 2020;85(104474):104474 Accessed 4 July 2021. https://doi.org/10.1016/j.meegid.2020.104474
   PubMedGoogle Scholar
• Guruprasad L. Human coronavirus spike protein-host receptor recognition. Prog Biophys Mol Biol. 2020;161:39.
   PubMed Web of Science ®Google Scholar
• Mesecar AD, Ratia K. Viral destruction of cell surface receptors. Proc Natl Acad Sci U S A. 2008;105:8807–8808.
   PubMed Web of Science ®Google Scholar
• Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining “host jump” of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23:468–478.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273 Accessed 8 August 2021.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095418/
   PubMed Web of Science ®Google Scholar
• Hu B, Ge X, Wang LF, et al. Bat origin of human coronaviruses: emerging and re-emerging pathogens in humans and animals susanna lau positive-strand RNA viruses. Virol J. 2015;12:1–10.
   PubMed Web of Science ®Google Scholar
• Donaldson EF, Haskew AN, Gates JE, et al. Metagenomic analysis of the viromes of three North American bat species: viral diversity among different bat species that share a common habitat. J Virol. 2010;84:13004–13018.
   PubMed Web of Science ®Google Scholar
• Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192.
   PubMed Web of Science ®Google Scholar
• Forni D, Cagliani R, Clerici M, et al. Molecular evolution of human coronavirus genomes. Trends Microbiol. 2017;25:35–48.
   PubMed Web of Science ®Google Scholar
• Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502.
   PubMed Web of Science ®Google Scholar
• Li N, Gu W, Lu C, et al. Characteristics of angiotensin I-converting enzyme 2, type II transmembrane serine protease 2 and 4 in tree shrew indicate it as a potential animal model for SARS-CoV-2 infection. Bioengineered. 2021;12:2836–2850.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs. J Med Virol. 2020;92:2105–2113.
   PubMed Web of Science ®Google Scholar
• Patra R, Chandra Das N, Mukherjee S. Targeting human TLRs to combat COVID‐19: a solution? J Med Virol. 2021;93:615–617.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. 2020. Bull World Health Organ. 2021;99(1):19–33F.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:127–147.
   PubMed Web of Science ®Google Scholar
• Li H, Liu SM, Yu XH, et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55:105951.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhu Y, Liu M, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020;17:765–767.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science. 2020;368:409–412.
   PubMed Web of Science ®Google Scholar
• Li YH, Hu CY, Wu NP, et al. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering. 2019;5:940–947.
   Web of Science ®Google Scholar
• Roe MK, Junod NA, Young AR, et al. Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19. J Gen Virol. 2021;102:001558.
   PubMed Web of Science ®Google Scholar
• Berry M, Fielding B, Gamieldien J. Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: homology modelling and molecular dynamic studies. BMC Struct Biol. 2015;15:4–13.
   PubMed Web of Science ®Google Scholar
• Shu T, Huang M, Wu D, et al. SARS-coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts. Virol Sin. 2020;35:321–329 Accessed 13 April 2021. https://doi.org/10.1007/s12250-020-00242-1
   PubMed Web of Science ®Google Scholar
• Ruan Z, Liu C, Guo Y, et al. SARS‐CoV‐2 and SARS‐CoV: virtual screening of potential inhibitors targeting RNA‐dependent RNA polymerase activity (NSP12). J Med Virol. 2020;92:26222.
   Google Scholar
• Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368:1499–1504.
   PubMed Web of Science ®Google Scholar
• El-Shabasy RM, Nayel MA, Taher MM, et al. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. Int J Biol Macromol. 2022;204:161–168.
   PubMed Web of Science ®Google Scholar
• Haque A, Pant AB. Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. J Autoimmun. 2022;127:102792.
   PubMed Web of Science ®Google Scholar
• Grint DJ, Wing K, Williamson E, et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Eurosurveillance. 2021;26:2100256 Accessed 09 February 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976383/
   Web of Science ®Google Scholar
• Mwenda M, Saasa N, Sinyange N, et al. Detection of B.1.351 SARS-CoV-2 variant strain — Zambia, December 2020. Morb Mortal Wkly Rep. 2021;70:280–282 Accessed 09 February 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344984/
   PubMed Web of Science ®Google Scholar
• WHO. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021; Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
   Google Scholar
• Chen J, Wang R, Gilby NB, et al. Omicron Variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62:412–422.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Mukherjee G, Mukherjee S. Chemotherapy vs. immunotherapy in combating nCOVID19: an update. Hum Immunol. 2021;82:649.
   PubMed Web of Science ®Google Scholar
• Hanley KA. The Double-Edged Sword: how evolution can make or break a live-attenuated virus vaccine. Evol Educ Outreach . 2011;4:635–643 Accessed 2 November 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314307/
   Google Scholar
• Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584:353–363.
   PubMed Web of Science ®Google Scholar
• Wieczorek M, Abualrous ET, Sticht J, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8:292.
   PubMed Web of Science ®Google Scholar
• Lin L, Ting S, Yufei H, et al. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. Virus Res. 2020;288:198082.
   PubMed Web of Science ®Google Scholar
• Qian Z, Ou X, Góes LGB, et al. Identification of the receptor-binding domain of the spike glycoprotein of human betacoronavirus HKU1. J Virol. 2015;89:8816–8827.
   PubMed Web of Science ®Google Scholar
• Chang CK, Hou MH, Chang CF, et al. The SARS coronavirus nucleocapsid protein - forms and functions. Antiviral Res. 2014;103:39–50.
   PubMed Web of Science ®Google Scholar
• Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:254.
   PubMed Web of Science ®Google Scholar
• Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362:1895–1896.
   PubMed Web of Science ®Google Scholar
• Liu R, Wang J, Shao Y, et al. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Res. 2018;150:30–38.
   PubMed Web of Science ®Google Scholar
• He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324:773–781.
   PubMed Web of Science ®Google Scholar
• Zang J, Gu C, Zhou B, et al. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. Cell Discov. 2020;6:1–4 Accessed 15 April 2021. https://doi.org/10.1038/s41421-020-00199-1
   PubMed Web of Science ®Google Scholar
• Jiaming L, Yanfeng Y, Yao D, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35:10–18.
   PubMed Web of Science ®Google Scholar
• Okba NM, Raj VS, Haagmans BL. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr Opin Virol. 2017;23:49–58.
   PubMed Web of Science ®Google Scholar
• Mou H, Raj VS, van Kuppeveld FJM, et al. The receptor binding domain of the new Middle East Respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013;87:9379–9383.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhang N, Tao X, et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015;11:1244–1250.
   PubMed Web of Science ®Google Scholar
• Ma C, Wang L, Tao X, et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine. 2014;32:6170–6176.
   PubMed Web of Science ®Google Scholar
• Tai W, Zhao G, Sun S, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375–382.
   PubMed Web of Science ®Google Scholar
• Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32:2100–2108.
   PubMed Web of Science ®Google Scholar
• Herst CV, Burkholz S, Sidney J, et al. An effective CTL peptide vaccine for Ebola Zaire based on survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. Vaccine. 2020;38:4464–4475 Accessed 5 July 2021. https://doi.org/10.1016/j.vaccine.2020.04.034
   PubMed Web of Science ®Google Scholar
• Pereyra F, Heckerman D, Carlson JM, et al. HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes. J Virol. 2014;88:12937–12948 Accessed 30 November 2020.
   PubMed Web of Science ®Google Scholar
• Chen HZ, Tang LL, Yu XL, et al. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. Infect Dis Poverty. 2020;9:88.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15.
   PubMed Web of Science ®Google Scholar
• Singh A, Thakur M, Sharma LK, et al. Designing a multi-epitope peptide based vaccine against SARS-CoV-2. Sci Rep. 2020;10:1–12.
   PubMed Web of Science ®Google Scholar
• Kalita P, Padhi AK, Zhang KYJ, et al. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020;145:104236.
   PubMed Web of Science ®Google Scholar
• Cao M, Su X, Jiang S. Broad-spectrum anti-coronavirus vaccines and therapeutics to combat the current COVID-19 pandemic and future coronavirus disease outbreaks. Stem Cell Reports. 2021;16:398–411.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of the tolerability, safety, immunogenicity and preventive efficacy of the epiVacCorona vaccine for the prevention of COVID-19. 2021 Accessed 15 April 2021; https://clinicaltrials.gov/ct2/show/NCT04780035
   Google Scholar
• Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495.
   PubMed Web of Science ®Google Scholar
• Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial Lancet Infect . . 2021;21:637–646 Accessed 8 March 2022. https://pubmed.ncbi.nlm.nih.gov/33485468/
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. Accessed 8 March 2022. http://www.thelancet.com/article/S0140673620326611/fulltext
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. Accessed 8 March 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Das NC, Chakraborty P, Bayry J, et al. In silico analyses on the comparative potential of therapeutic human monoclonal antibodies against newly emerged SARS-CoV-2 variants bearing mutant spike protein. Front Immunol. 2022;12:5576.
   Web of Science ®Google Scholar
• Choudhury A, Das NC, Patra R, et al. Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an approach. Future Virol. 2021;16:277–291.
   Web of Science ®Google Scholar
• Varona JF, Landete P, Lopez-Martin JA, et al. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance. 2022;5:e202101200 Accessed 8 March 2022. https://pubmed.ncbi.nlm.nih.gov/35012962/
   PubMed Web of Science ®Google Scholar
• White KM, Rosales R, Yildiz S, et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021;371:926 Accessed 8 March 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963220/
   PubMed Web of Science ®Google Scholar
• Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–468 Accessed 14 July 2020. https://pubmed.ncbi.nlm.nih.gov/32353859/
   PubMed Web of Science ®Google Scholar
• Han Y, Král P. Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano. 2020;14:5143–5147.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766–788.
   PubMed Web of Science ®Google Scholar
• Momattin H, Mohammed K, Zumla A, et al. Therapeutic options for Middle East Respiratory Syndrome coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis. 2013;17:e792–8.
   PubMed Web of Science ®Google Scholar
• Chang CK, Lo SC, Wang YS, et al. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov Today. 2016;21:562–572.
   PubMed Web of Science ®Google Scholar
• Alamri MA, Tahir Ul Qamar M, Afzal O, et al. Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation. J Mol Liq. 2021;330:115699.
   PubMed Web of Science ®Google Scholar
• Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4(11):1443–1467 Accessed 27 November 2020. https://www.future-science.com/doi/abs/10.4155/tde.13.104
   PubMedGoogle Scholar
• Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. J Infect Public Health. 2018;11(1):9–17 Accessed 15 April 2021. https://pubmed.ncbi.nlm.nih.gov/28864360/
   PubMed Web of Science ®Google Scholar
• Wang X, Xia S, Zhu Y, et al. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein Cell. 2021;12(2):84–88 Accessed 15 April 2021. https://doi.org/10.1007/s13238-020-00806-7
   PubMed Web of Science ®Google Scholar
• Chourasia R, Padhi S, Chiring Phukon L, et al. A potential peptide from soy cheese produced using lactobacillus delbrueckii WS4 for effective inhibition of SARS-CoV-2 main protease and S1 glycoprotein. Front Mol Biosci. 2020;7:601753.
   PubMed Web of Science ®Google Scholar
• Wong F, Ong J, Chai T. Identification of putative cell-entry-inhibitory peptides against SARS-CoV-2 from edible insects: an in silico study. eFood. 2020;1(5):357–368.
   Google Scholar
• Ling R, Dai Y, Huang B, et al. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2. Peptides. 2020;130:170328.
   PubMed Web of Science ®Google Scholar
• Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343–355. DOI:10.1038/s41422-020-0305-x.
   PubMed Web of Science ®Google Scholar
• Kabra R, Singh S. Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics. Biochim Biophys Acta - Mol Basis Dis. 2021;1867(1):165978. Accessed 8 March 2022. https://doi.org/10.1016/j.bbadis.2020.165978
   PubMed Web of Science ®Google Scholar
• Abedin MM, Chourasia R, Chiring Phukon L, et al. Characterization of ACE inhibitory and antioxidant peptides in yak and cow milk hard chhurpi cheese of the Sikkim Himalayan region. Food Chem X . 2022;13:100231 .
   PubMedGoogle Scholar
• Padhi S, Chourasia R, Kumari M, et al. Production and characterization of bioactive peptides from rice beans using bacillus subtilis. Bioresour Technol. 2022;351:126932.
   PubMed Web of Science ®Google Scholar
• Chourasia R, Kumari R, Singh SP, et al. Characterization of native lactic acid bacteria from traditionally fermented chhurpi of Sikkim himalayan region for the production of chhurpi cheese with enhanced antioxidant effect. LWT Food Sci. Technol. 2022;154:112801.
   Web of Science ®Google Scholar
• Sanjukta S, Padhi S, Sarkar P, et al. Production, characterization and molecular docking of antioxidant peptides from peptidome of kinema fermented with proteolytic Bacillus spp. Food Res Int. 2021;141:110161.
   PubMed Web of Science ®Google Scholar
• Chai KF, Voo AYH, Chen WN. Bioactive peptides from food fermentation: a comprehensive review of their sources, bioactivities, applications, and future development. Compr Rev Food Sci Food Saf. 2020;19(6):3825–3885 Accessed 6 December 2020. https://onlinelibrary.wiley.com/doi/full/10.1111/1541-4337.12651
   PubMed Web of Science ®Google Scholar
• Padhi S, Sanjukta S, Chourasia R, et al. A multifunctional peptide from bacillus fermented soybean for effective inhibition of SARS-CoV-2 S1 receptor binding domain and modulation of toll like receptor 4: a molecular docking study. Front Mol Biosci. 2021;8:636647.
   PubMed Web of Science ®Google Scholar
• Luo Z, Su K, Zhang X. Potential of plant proteins digested in silico by gastrointestinal enzymes as nutritional supplement for COVID-19 patients. Plant Foods Hum Nutr. 2020;75(4):583–591.
   PubMed Web of Science ®Google Scholar
• Wong F-C, Ong J-H, Chai -T-T. SARS-CoV-2 spike protein-, main protease- and papain-like-protease-targeting peptides from seed proteins following gastrointestinal digestion: an in silico study. Phytomed Plus. 2021;1(1):100016. DOI:10.1016/j.phyplu.2020.100016.
   PubMedGoogle Scholar
• Yao Y, Luo Z, Zhang X. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients. Food Funct. 2020;11(6):5565–5572.
   PubMed Web of Science ®Google Scholar
• Aguilar CN, Ruiz HA, Rubio Rios A, et al. Emerging strategies for the development of food industries. Bioengineered. 2019;10(1):522–537 Accessed 10 February 2022. https://www.tandfonline.com/doi/abs/10.1080/21655979.2019.1682109
   PubMed Web of Science ®Google Scholar
• Shwaiki LN, Lynch KM, Arendt EK. Future of antimicrobial peptides derived from plants in food application – a focus on synthetic peptides. Trends Food Sci Technol. 2021;112:312–324.
   Web of Science ®Google Scholar
• Hu H, Li L, Kao RY, et al. Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J Comb Chem. 2005;7:648–656. Accessed 16 April 2021. https://pubs.acs.org/doi/abs/10.1021/cc0500607
   PubMedGoogle Scholar
• Han DP, Penn-Nicholson A, Cho MW. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology. 2006;350:15–25.
   PubMed Web of Science ®Google Scholar
• Yang Y, Deng Y, Wen B, et al. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. Viral Immunol. 2014;27:543–550.
   PubMed Web of Science ®Google Scholar
• Xia S, Liu Q, Wang Q, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014;194:200–210.
   PubMed Web of Science ®Google Scholar
• Yang J, Petitjean SJL, Koehler M, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020;11:4541.
   PubMed Web of Science ®Google Scholar
• Sainz B, Mossel EC, Gallaher WR, et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res. 2006;120:146–155.
   PubMed Web of Science ®Google Scholar
• Wang X, Xia S, Wang Q, et al. Broad-spectrum coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus diseases. Int J Mol Sci. 2020;21:3843.
   PubMed Web of Science ®Google Scholar
• Xia S, Lan Q, Pu J, et al. Potent MERS-CoV fusion inhibitory peptides identified from HR2 domain in spike protein of bat coronavirus HKU4. Viruses. 2019;11:56.
   PubMed Web of Science ®Google Scholar
• Bosch BJ, Martina BEE, Van Der Zee R, et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A. 2004;101:8455–8460.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV - A target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–236.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu D, Yan H, et al. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol. 2020;94:e00635.
   PubMed Web of Science ®Google Scholar
• Báez-Santos YM, St.John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21–38.
   PubMed Web of Science ®Google Scholar
• Farhat A, Hlima B, Khemakhem B, et al. Apigenin analogues as SARS-CoV-2 main protease inhibitors: in-silico screening approach. Bioengineered. 2022;13:3350–3361.
   PubMed Web of Science ®Google Scholar
• Gan YR, Huang H, Huang YD, et al. Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase. Peptides. 2006;27:622–625.
   PubMed Web of Science ®Google Scholar
• Kumar V, Shin JS, Shie JJ, et al. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017;141:101–106.
   PubMed Web of Science ®Google Scholar
• Shao YM, Bin YW, Kuo TH, et al. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. Bioorg Med Chem. 2008;16:4652–4660.
   PubMed Web of Science ®Google Scholar
• Day CW, Baric R, Cai SX, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395:210–222.
   PubMed Web of Science ®Google Scholar
• Zhang HZ, Zhang H, Kemnitzer W, et al. Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. J Med Chem. 2006;49:1198–1201.
   PubMed Web of Science ®Google Scholar
• Du Q-S, Sun H, Chou K-C. Inhibitor design for SARS coronavirus main protease based on “distorted key theory. Med Chem. 2006;3:1–6.
   Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. Accessed 15 July 2021. http://doi.org/10.1038/s41586-020-2223-y
   PubMed Web of Science ®Google Scholar
• Ibrahim TM, Ismail MI, Bauer MR, et al. Supporting SARS-CoV-2 papain-like protease drug discovery: in silico methods and benchmarking. Front Chem. 2020;8:592289.
   PubMed Web of Science ®Google Scholar
• Decroly E, Imbert I, Coutard B, et al. Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity. J Virol. 2008;82:8071–8084.
   PubMed Web of Science ®Google Scholar
• Morales P, Curtis NL, Sandra GZ, et al. Interfering with mRNA methylation by the 2’-O-methyltransferase (NSP16) from SARS-CoV-2 to tackle the COVID-19 disease. Catalysts. 2020;10:11023.
   Web of Science ®Google Scholar
• Chen Y, Su C, Ke M, et al. Biochemical and structural insights into the mechanisms of sars coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex. PLoS Pathog. 20117;7(10):e1002294. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192843/
   PubMed Web of Science ®Google Scholar
• Ke M, Chen Y, Wu A, et al. Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2’-O-methyltransferase activity of nsp10/nsp16 complex. Virus Res. 2012;167:322–328. Accessed 16 April 2021. https://linkinghub.elsevier.com/retrieve/pii/S0168170212001888
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun Y, Wu A, et al. Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis . J Virol. 2015;89:8416–8427. Accessed 16 April 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524257/
   PubMed Web of Science ®Google Scholar
• Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Ikram S, Ahmad F, et al. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) – a drug repurposing study. Heliyon. 2020;6:e04502.
   PubMed Web of Science ®Google Scholar
• Fan Q, Zhang B, Ma J, et al. Safety profile of the antiviral drug remdesivir: an update. Biomed Pharmacother. 2020;130:110532.
   PubMed Web of Science ®Google Scholar
• Kumar V, Bansal V, Madhavan A, et al. Active pharmaceutical ingredient (API) chemicals: a critical review of current biotechnological approaches. Bioengineered. 2022;13:4309–4327.
   PubMed Web of Science ®Google Scholar
• Sarsaiya S, Shi J, Chen J. Bioengineering tools for the production of pharmaceuticals: current perspective and future outlook. Bioengineered. 2019;10:469–492.
   PubMed Web of Science ®Google Scholar
• Ahn DG, Lee W, Choi JK, et al. Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication. Antiviral Res. 2011;91:1–10.
   PubMed Web of Science ®Google Scholar
• Ansari MA, Almatroudi A, Alzohairy MA, et al. Lipid-based nano delivery of tat-peptide conjugated drug or vaccine–promising therapeutic strategy for SARS-CoV-2 treatment. Expert Opin Drug Deliv. 2020;17:1671–1674.
   PubMed Web of Science ®Google Scholar
• Otvos L, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2014;2:00062.
   PubMed Web of Science ®Google Scholar
• Gentilucci L, De Marco R, Cerisoli L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des. 2010;16:3185–3203.
   PubMed Web of Science ®Google Scholar
• Manteghi R, Pallagi E, Olajos G, et al. Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach. Eur J Pharm Sci. 2020;144:105197.
   PubMed Web of Science ®Google Scholar
• Hedegaard SF, Bruhn DS, Khandelia H, et al. Shuffled lipidation pattern and degree of lipidation determines the membrane interaction behavior of a linear cationic membrane-active peptide. J Colloid Interface Sci. 2020;578:584–597.
   PubMed Web of Science ®Google Scholar
• Kurrikoff K, Vunk B, Langel Ü. Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics. Expert Opin Biol Ther. 2020;20:1–10.
   PubMedGoogle Scholar
• Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363:938–947. Accessed 17 April 2021. https://linkinghub.elsevier.com/retrieve/pii/S0140673604157887
   PubMed Web of Science ®Google Scholar
• Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067. Accessed 17 April 2021. http://www.nature.com/articles/ncomms4067
   PubMed Web of Science ®Google Scholar